Tirzepatide (Mounjaro) in Israel: What the Research Actually Shows
The GLP-1/GIP dual agonist that produces an average weight loss of up to ~22% in the SURMOUNT trials — a scientific review, regulatory status in Israel, and safety warnings, without the marketing hype.
What is tirzepatide?
Tirzepatide (brand name Mounjaro for diabetes, and Zepbound for obesity) is a dual agonist that simultaneously activates the GLP-1 and GIP receptors. In the SURMOUNT-1 trials, participants on the high dose lost an average of about 20.9% of body weight over 72 weeks. In Israel, the drug is registered and marketed to treat type 2 diabetes, and its use requires a prescription and medical follow-up.
How tirzepatide works
Tirzepatide is the first of the "dual agonist" family: a single molecule that binds to two metabolic receptors — GLP-1 and GIP. GLP-1 reduces appetite, slows gastric emptying, and improves insulin secretion, while the added GIP activity may improve insulin sensitivity and how the body handles fat.
This combination is why tirzepatide produced a higher average weight loss in trials than semaglutide (Ozempic/Wegovy), becoming a new reference point in the drug treatment of obesity and diabetes.
SURMOUNT data — what the trials showed
- SURMOUNT-1: an average loss of up to ~20.9% of body weight at the 15 mg dose over 72 weeks (participants without diabetes).
- Dose-dependent data: as the dose increased, efficacy increased accordingly.
- Improvements were reported in accompanying metabolic measures — blood pressure, blood sugar, and lipid profile.
- In the SURPASS trials for type 2 diabetes, tirzepatide significantly improved HbA1c values.
Regulatory status in Israel
Mounjaro (tirzepatide) is registered in the Israeli Ministry of Health drug registry to treat type 2 diabetes. Like other GLP-1 drugs, it requires a doctor's prescription and is not available as a free supplement.
Health-basket inclusion, approved indications, and reimbursement terms change from time to time. Verify the current status with your treating physician, your HMO, and the official drug label before any decision.
Safety and side effects
The most common side effects are gastrointestinal: nausea, diarrhea, constipation, and vomiting — usually at the start of treatment and when increasing the dose.
There are warnings about a rare risk of pancreatitis, as well as a boxed warning (based on animal models) regarding thyroid tumors. The treatment is not suitable for everyone and requires evaluation and ongoing follow-up by a qualified physician.
Warning: grey market and unregulated products
Around the high demand, unregulated sellers appear offering "research-only" tirzepatide or powders for self-injection. These carry serious risks: unknown purity, incorrect dosing, contamination, and lack of medical supervision.
The efficacy and safety data from the trials apply only to the regulated drug given under medical supervision — not to a vial bought online. PepVero does not sell or supply any compounds.
15 mg dose over 72 weeks in the SURMOUNT-1 trial (participants without diabetes).
Frequently asked questions
What is the difference between Mounjaro and Ozempic?
Ozempic (semaglutide) is a single GLP-1 agonist. Mounjaro (tirzepatide) is a dual agonist that activates both GLP-1 and GIP. In trials tirzepatide showed a higher average weight loss, but the medical choice depends on the patient and the physician's judgment.
Is tirzepatide approved in Israel?
Yes, Mounjaro is registered in Israel to treat type 2 diabetes and requires a prescription. Indications and reimbursement terms may change — verify with your physician and HMO.
How much weight can you lose with tirzepatide?
In the SURMOUNT-1 trial, participants without diabetes lost an average of up to ~20.9% of body weight at the 15 mg dose over 72 weeks. Individual results vary and depend on dose, diet, and lifestyle.
What are the main side effects?
The most common are gastrointestinal — nausea, diarrhea, constipation, and vomiting, mainly at the start of treatment. There are rarer warnings (pancreatitis, a thyroid warning). Medical follow-up is required.
Can you buy tirzepatide online?
Do not purchase tirzepatide from unregulated sources. "Grey market" products carry risks of purity, contamination, and incorrect dosing, and the trial safety data do not apply to them. Use requires a prescription and medical follow-up.
Sources
This page is for educational and research information only and is not medical advice, diagnosis, or a recommendation to obtain or use any compound. Tirzepatide is a prescription drug and requires medical supervision. Do not obtain or use unregulated peptides. Consult a qualified physician.
Go deeper into the data
Compare metabolic peptides side by side, check the regulatory status in Israel, and read the evidence-scoring methodology.